Neovacs SA Valuation
| ALNEV Stock | EUR 0.0002 0.0001 33.33% |
Neovacs SA seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Neovacs SA from analyzing the firm fundamentals such as Operating Margin of (620.28) %, shares outstanding of 590.99 M, and Return On Equity of -0.27 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Neovacs SA's price fluctuation is out of control at this time. Calculation of the real value of Neovacs SA is based on 3 months time horizon. Increasing Neovacs SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Neovacs SA's intrinsic value may or may not be the same as its current market price of 0.0002, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0E-4 | Real 1.92E-4 | Hype 2.22E-4 | Naive 1.84E-4 |
The intrinsic value of Neovacs SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neovacs SA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neovacs SA helps investors to forecast how Neovacs stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neovacs SA more accurately as focusing exclusively on Neovacs SA's fundamentals will not take into account other important factors: Neovacs SA Total Value Analysis
Neovacs SA is presently projected to have takeover price of (30.4 M) with market capitalization of 531.89 K, debt of 0, and cash on hands of 1.42 M. The negative valuation of Neovacs SA may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Neovacs SA fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(30.4 M) | 531.89 K | 0 | 1.42 M |
Neovacs SA Investor Information
The company has price-to-book (P/B) ratio of 0.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Neovacs SA had not issued any dividends in recent years. The entity had 10000:1 split on the 31st of August 2024. Based on the key measurements obtained from Neovacs SA's financial statements, Neovacs SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Neovacs SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neovacs SA has an asset utilization ratio of 0.0465 percent. This connotes that the Company is making €4.65E-4 for each dollar of assets. An increasing asset utilization means that Neovacs SA is more efficient with each dollar of assets it utilizes for everyday operations.Neovacs SA Profitability Analysis
The company reported the revenue of 22.59 K. Net Loss for the year was (11.84 M) with loss before overhead, payroll, taxes, and interest of (4.54 M).About Neovacs SA Valuation
The stock valuation mechanism determines Neovacs SA's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Neovacs SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neovacs SA. We calculate exposure to Neovacs SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neovacs SA's related companies.Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 24 people.
8 Steps to conduct Neovacs SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Neovacs SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Neovacs SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Neovacs SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Neovacs SA's revenue streams: Identify Neovacs SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Neovacs SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Neovacs SA's growth potential: Evaluate Neovacs SA's management, business model, and growth potential.
- Determine Neovacs SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Neovacs SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.